Antidiabetic tricyclic compounds

US10000454B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Tesfaye Biftu · Belmont, US
• Purakkattle Biju · Piscataway, US
• Timothy A. Blizzard · Middletown, US
• Zhengxia Chen · Shanghai, CN
• Matthew J. Clements · Old Bridge, US
• Mingxiang Cui · Shanghai, CN
• Jessica Frie · Harleysville, US
• William K. Hagmann · Westfield, US
• Bin Hu · Mesa, US
• Hubert Josien · Hoboken, US
• Anilkumar G. Nair · Edison, US
• Christopher W. Plummer · Hoboken, US
• Cheng Zhu · Edison, US

Key dates

• Filing date: May 19, 2015
• Grant date: Jun 19, 2018
• Expiry date: May 19, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2603/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.